{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:58:55Z","timestamp":1790409535577,"version":"4.1.0"},"reference-count":28,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"unspecified","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,5,6]]},"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:p>Interleukin-2 (IL-2) was one of the first immunotherapies in the treatment of patients with cancer. High-dose bolus IL-2 (HD IL-2) can induce durable complete or partial tumor regression in a small proportion of advanced melanoma and renal cell carcinoma patients. However, its potential for life-threatening side effects and requirement for inpatient administration limits its use to patients with excellent organ function treated at experienced centers. In 2024, following decades of foundational work at the National Cancer Institute, lifileucel became the first FDA-approved tumor-infiltrating lymphocyte (TIL) therapy for cancer. HD IL-2 is routinely given after TIL infusion to promote the survival and proliferation of the T cell product. In this context, fewer doses are given, and the parameters for holding an IL-2 dose are more conservative, as compared with HD IL-2 monotherapy, which has now fallen out of routine use. The lower number of doses, and possibly the effects of the preparative lymphodepletion, result in much less cytokine-related toxicity. Nevertheless, concerns related to HD IL-2 toxicity persist and possibly impact decisions to offer TIL when indicated. Here, we discuss the differences in the administration of HD IL-2 as a monotherapy vs an adjunctive therapy following TIL infusion, in an effort to demystify the toxicity of HD IL-2 in the era of cellular therapy.<\/jats:p>","DOI":"10.1136\/jitc-2024-011119","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T04:45:15Z","timestamp":1748580315000},"page":"e011119","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Role of high-dose interleukin-2 for melanoma in the age of cellular therapy"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7979-8953","authenticated-orcid":false,"given":"Elizabeth","family":"Buchbinder","sequence":"first","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T","family":"Lotze","sequence":"additional","affiliation":[{"name":"University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5248-4356","authenticated-orcid":false,"given":"Kim A","family":"Margolin","sequence":"additional","affiliation":[{"name":"Medical Oncology, City of Hope National Medical Center, Duarte, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodabe","family":"Amaria","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2337-5898","authenticated-orcid":false,"given":"Amod","family":"Sarnaik","sequence":"additional","affiliation":[{"name":"H Lee Moffitt Canc Ctr, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Seery","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2307-7030","authenticated-orcid":false,"given":"Zeynep","family":"Eroglu","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6697-3516","authenticated-orcid":false,"given":"Karam","family":"Khaddour","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6422-2997","authenticated-orcid":false,"given":"Allison","family":"Betof Warner","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4932-9873","authenticated-orcid":false,"given":"Harriet M","family":"Kluger","sequence":"additional","affiliation":[{"name":"Medical Oncology, Yale University School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4137-9662","authenticated-orcid":false,"given":"Mario","family":"Sznol","sequence":"additional","affiliation":[{"name":"Yale Cancer Center, Yale University, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3901-9924","authenticated-orcid":false,"given":"Michael B","family":"Atkins","sequence":"additional","affiliation":[{"name":"Oncology, Georgetown University, Washington, District of Columbia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F","family":"Mcdermott","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3877-3984","authenticated-orcid":false,"given":"Ann W","family":"Silk","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"2025100314552552000_13.5.e011119.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2015.10.003"},{"key":"2025100314552552000_13.5.e011119.2","doi-asserted-by":"publisher","DOI":"10.1038\/nri3156"},{"key":"2025100314552552000_13.5.e011119.3","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aat1482","article-title":"Revisiting IL-2: Biology and therapeutic prospects","volume":"3","author":"Abbas","year":"2018","journal-title":"Sci Immunol"},{"key":"2025100314552552000_13.5.e011119.4","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba5464","article-title":"Interleukin-2 signals converge in a lymphoid-dendritic cell pathway that promotes anticancer immunity","volume":"12","author":"Raeber","year":"2020","journal-title":"Sci Transl Med"},{"key":"2025100314552552000_13.5.e011119.5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1171"},{"key":"2025100314552552000_13.5.e011119.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00722-1"},{"key":"2025100314552552000_13.5.e011119.7","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1490019"},{"key":"2025100314552552000_13.5.e011119.8","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1163462","article-title":"Role of IL-2 in cancer immunotherapy","volume":"5","author":"Jiang","year":"2016","journal-title":"Oncoimmunology"},{"key":"2025100314552552000_13.5.e011119.9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.4.661"},{"key":"2025100314552552000_13.5.e011119.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.5448"},{"key":"2025100314552552000_13.5.e011119.11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.3.688"},{"key":"2025100314552552000_13.5.e011119.12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.7.2105"},{"key":"2025100314552552000_13.5.e011119.13","first-page":"S11","article-title":"High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update","volume":"6 Suppl 1","author":"Atkins","year":"2000","journal-title":"Cancer J Sci Am"},{"key":"2025100314552552000_13.5.e011119.14","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0155-8"},{"key":"2025100314552552000_13.5.e011119.15","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0522-3"},{"key":"2025100314552552000_13.5.e011119.16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.00.240"},{"key":"2025100314552552000_13.5.e011119.17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0116"},{"key":"2025100314552552000_13.5.e011119.18","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005755","article-title":"Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study","volume":"10","author":"Chesney","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025100314552552000_13.5.e011119.19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00612"},{"key":"2025100314552552000_13.5.e011119.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2210233"},{"key":"2025100314552552000_13.5.e011119.21","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0279-5"},{"key":"2025100314552552000_13.5.e011119.22","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0307-5"},{"key":"2025100314552552000_13.5.e011119.23","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-014-0026-0"},{"key":"2025100314552552000_13.5.e011119.24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.8153"},{"key":"2025100314552552000_13.5.e011119.25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008735","article-title":"Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy","volume":"12","author":"Betof Warner","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2025100314552552000_13.5.e011119.26","doi-asserted-by":"crossref","unstructured":"Hassel JC , Sarnaik A , Chesney J , et al . Number of il-2 doses and clinical outcomes of tumor-infiltrating lymphocyte (til) cell therapy: post hoc analysis of the c-144-01 trial of lifileucel in patients with advanced melanoma. ESMO Immuno-Oncology and Technology; 2022:100140. doi:10.1016\/j.iotech.2022.100140","DOI":"10.1016\/j.iotech.2022.100140"},{"key":"2025100314552552000_13.5.e011119.27","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines13010069","article-title":"Efficacy of Anti-Cancer Immune Responses Elicited Using Tumor-Targeted IL-2 Cytokine and Its Derivatives in Combined Preclinical Therapies","volume":"13","author":"Balkhi","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"2025100314552552000_13.5.e011119.28","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1158\/2159-8290.CD-24-0645","article-title":"Lung Cancer Adoptive Cell Therapy: Inspiring TIL ACT Comes Center Stage","volume":"14","author":"Lotze","year":"2024","journal-title":"Cancer Discov"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-011119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T21:55:32Z","timestamp":1759528532000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-011119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":28,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,30]]},"published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1136\/jitc-2024-011119"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-011119","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]}}}